(AMPH) Amphastar P - Ratings and Ratios

Amphastar Pharmaceuticals (NASDAQ:AMPH) is a bio-pharmaceutical company with a focus on injectable, inhalation, and intranasal products. Operating primarily in the U.S., China, and France, they offer a mix of generic and proprietary drugs. Their product portfolio includes BAQSIMI, a nasal spray for severe hypoglycemia, and Primatene Mist, an OTC epinephrine inhaler for mild asthma. Enoxaparin, used to prevent deep vein thrombosis, is another key product, alongside Rextovy and Naloxone for opioid overdose treatment. They also provide Glucagon emergency kits and Cortrosyn for diagnostic purposes.

The companys range extends to anesthetic and emergency products such as Amphadase, Epinephrine injections, and Lidocaine jelly. They distribute insulin APIs, a significant part of their business. Amphastar is actively developing generics, biosimilars, and an intranasal epinephrine spray, showcasing their commitment to innovation and pipeline growth.

Financially, Amphastar has a market cap of around $1.5 billion, with a P/E ratio of 10.55, indicating a reasonable valuation. Their P/B ratio of 2.10 and P/S of 2.06 are key metrics for investors assessing the companys financial health and market position.